146 related articles for article (PubMed ID: 10714366)
1. Gs alpha mutations in hyperfunctioning thyroid adenomas.
Murakami M; Kamiya Y; Yanagita Y; Mori M
Arch Med Res; 1999; 30(6):514-21. PubMed ID: 10714366
[TBL] [Abstract][Full Text] [Related]
2. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
3. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
Tonacchera M; Agretti P; Chiovato L; Rosellini V; Ceccarini G; Perri A; Viacava P; Naccarato AG; Miccoli P; Pinchera A; Vitti P
J Clin Endocrinol Metab; 2000 Jun; 85(6):2270-4. PubMed ID: 10852462
[TBL] [Abstract][Full Text] [Related]
4. Primary culture of cells from hyperfunctioning thyroid adenoma with an activating mutation of G alphas.
Kamiya Y; Murakami M; Yanagita Y; Koitabashi H; Nagamachi Y; Hosoi Y; Ogiwara T; Mizuma H; Iriuchijima T; Mori M
Mol Cell Endocrinol; 1998 Mar; 138(1-2):137-42. PubMed ID: 9685222
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
6. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
Spambalg D; Sharifi N; Elisei R; Gross JL; Medeiros-Neto G; Fagin JA
J Clin Endocrinol Metab; 1996 Nov; 81(11):3898-901. PubMed ID: 8923835
[TBL] [Abstract][Full Text] [Related]
7. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
8. The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas.
Brunetti A; Chiefari E; Filetti S; Russo D
Endocrinology; 2000 Feb; 141(2):722-30. PubMed ID: 10650954
[TBL] [Abstract][Full Text] [Related]
9. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
10. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions.
Arturi F; Scarpelli D; Coco A; Sacco R; Bruno R; Filetti S; Russo D
Thyroid; 2003 Apr; 13(4):341-3. PubMed ID: 12804102
[TBL] [Abstract][Full Text] [Related]
14. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features.
Arturi F; Capula C; Chiefari E; Filetti S; Russo D
Exp Clin Endocrinol Diabetes; 1998; 106(3):234-6. PubMed ID: 9710366
[TBL] [Abstract][Full Text] [Related]
16. Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia.
Ringel MD; Saji M; Schwindinger WF; Segev D; Zeiger MA; Levine MA
J Clin Endocrinol Metab; 1998 Feb; 83(2):554-9. PubMed ID: 9467574
[TBL] [Abstract][Full Text] [Related]
17. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
18. The natural history of thyroid autonomy and hot nodules.
Corvilain B
Ann Endocrinol (Paris); 2003 Feb; 64(1):17-22. PubMed ID: 12707627
[TBL] [Abstract][Full Text] [Related]
19. Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors.
Mantovani G; Bondioni S; Lania AG; Corbetta S; de Sanctis L; Cappa M; Di Battista E; Chanson P; Beck-Peccoz P; Spada A
J Clin Endocrinol Metab; 2004 Jun; 89(6):3007-9. PubMed ID: 15181091
[TBL] [Abstract][Full Text] [Related]
20. G protein abnormalities in pituitary adenomas.
Spada A; Lania A; Ballarè E
Mol Cell Endocrinol; 1998 Jul; 142(1-2):1-14. PubMed ID: 9783897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
